Navigation Links
Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team
Date:5/22/2013

Blue Earth, MN (PRWEB) May 22, 2013

Express Diagnostics Int’l, Inc. (EDI), and Royal Medical Supplies Pty Ltd are pleased to announce a sponsorship agreement with Erebus Motorsport V8. Royal Medical is the Australian and New Zealand distributor of DrugCheck® onsite testing devices, manufactured by EDI. The Erebus Motorsport V8 Supercar Team participated in the Austin 400 May 17-19 in Austin, Texas.

Royal Medical Supplies has entered into an agreement that involves each car of the Erebus Motorsport team displaying the Royal Medical name and logo in Australian racing events. Erebus owns and races three Mercedes-Benz E63 AMG V8 Supercars in the Australian V8 Supercar series — the Australian equivalent to the American NASCAR® series. For races held in the U.S., the team’s cars will also display the DrugCheck logo.

"We're very excited about partnering with Erebus Motorsport, which races the Mercedes-Benz AMG, a new make of race car for the V8 Supercar series,” says Gavin Holland, director of Royal Medical Supplies. “This motor racing championship appeals to a high proportion of Australians and New Zealanders and our target customers will be able to enjoy some of the on-track and off-track benefits resulting from this arrangement. The cars competing in the championship held in Austin, Texas, displayed the DrugCheck logo as well, providing additional media and on-track exposure for the brand.”

While sports team and event sponsorship is new to Express Diagnostics, the company welcomes Royal Medical’s efforts to raise the visibility of the DrugCheck brand. “We value our partnership with Royal Medical Supplies and appreciate Gavin’s commitment to promoting this U.S.-made product,” says Rich Strasser, COO of Express Diagnostics. “It was exciting to see the DrugCheck logo on the Erebus Motorsport cars during the Austin 400. We’d like to thank Royal Medical both for their sponsorship of the team and their continued support.”

Erebus Motorsport next races in the Skycity Triple Crown June 14-16 in Darwin, Australia.

About Express Diagnostics Int’l, Inc.
Express Diagnostics Int’l manufactures and distributes DrugCheck® on-site urine and saliva screening devices for the detection of drugs of abuse, as well as a growing catalog of health screening devices. With accuracy comparable to laboratory testing, Express Diagnostics onsite devices provide a variety of industries fast, cost-effective alternatives to higher-priced lab services. Learn more at drugcheck.com.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10754553.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Tom Karagiannis, Ph.D. Awarded Future Fellowship by Australian Research Council (ARC)
2. Australian Discovered Biomarkers Map Path to New Blood Test for Bowel Cancer
3. Algae.Tec Announces Commencement of Australian Advanced Biofuels Facility Commissioning
4. Hemaclear Announces First Annual Italian Distributor and User Conference: May 22, 2013 in Rome, Italy
5. Vertilon Signs Crisel Instruments as its Distributor in Italy
6. Life Technologies Acquires KDR Biotech Co., LTD., Leading Reagents Distributor
7. JG Finneran Associates Appoints Chebios as its Exclusive Distributor in Italy
8. UK supplier of graphenes announces exclusive sales agency agreement with leading USA distributor
9. Ingenuity Systems and Affymetrix Partner to Eliminate Microarray Expression Analysis Bottleneck
10. Express Genes by Eurofins MWG Operon Offers 4 Day Delivery of Synthetic Genes
11. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):